PolyNovo |
Market Cap (3-Oct) $621,757,760 (311th) |
Close (30-Jun) $1.55 |
Volume (30-Jun) 1,225,647 |
Shortsold (28-Sep) 50,391,477 (7.29%) (34th) |
|
52w High $1.56 |
52w Low $0.81 |
P/E 97.09 |
EPS 0.01 |
[ARTICLE] PolyNovo sales growth slows as lockdowns hit surgery rates
A news article has been posted about PolyNovo on the AFR. The article was published around , on 23 February 2021 at 12:06pm.
Skin regeneration biotechnology company PolyNovo’s slowdown in second quarter sales constrained its revenue growth to 25.3 per cent for the first half, as it hit $12.8 million. The company, which makes a dermal scaffold for burns and wounds based on a biodegradable temporising matrix called NovoSorb BTM,
Read ArticlePNV was $2.41 at the close of trade on 22 February 2021
| Recent Articles about ASX:PNV | |
|---|---|
| 23-Sep | Cadence Capital Limited ANNUAL REPORT 2026 - AFR
company-announcements.afr.com |
| 22-Sep | ASX Announcement Australian Clinical Labs Limited Tuesday ... - AFR
company-announcements.afr.com |
| 22-Sep | Australian Clinical Labs Limited - 2026 Annual General Meeting - AFR
company-announcements.afr.com |
| 17-Sep | PolyNovo Appoints Dean Phizacklea and Andrew Price as Non ...
company-announcements.afr.com |
| 16-Sep | CADENCE OPPORTUNITIES FUND LIMITED - AFR
company-announcements.afr.com |
| 16-Sep | PolyNovo Limited (ASX: PNV) | For the year ended 30 June 2026
company-announcements.afr.com |
| 22-Aug | 605 Page 1 of 3 - AFR
company-announcements.afr.com |
| 20-Jun | 604 Page 1 of 4 Form 604 Corporations Act 2001 Section 671B ...
company-announcements.afr.com |
| 20-Jun | J.P. MORGAN SECURITIES AUSTRALIA LIMITED JPMORGAN ...
company-announcements.afr.com |
| 12-Jun | PolyNovo U.S. Pivotal Trial – Clinical Study Report Finalised & PMA ...
company-announcements.afr.com |
| Tracked |
Find all articles about PolyNovo, including others on the AFR, on the media page.
You must be logged in to post a reply.